Molecular structure of meloxicam
Find information on thousands of medical conditions and prescription drugs.

Meloxicam

Meloxicam is a nonsteroidal anti-inflammatory drug used to relieve the symptoms of arthritis, primary dysmenorrhoea, pyrexia; and as an analgesic, especially where there is an inflammatory component. It is closely related to piroxicam. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
Macrodantin
Maprotiline
Marcaine
Marezine
Marijuana
Marinol
Marplan
Matulane
Maxair
Maxalt
Maxolon
MDMA
Measurin
Mebendazole
Mebendazole
Meclofenoxate
Medrol
Mefenamic acid
Mefloquine
Melagatran
Melarsoprol
Meloxicam
Melphalan
Memantine
Metadate
Metamfetamine
Metamizole sodium
Metandienone
Metaxalone
Metenolone
Metformin
Methadone
Methamphetamine
Methaqualone
Metharbital
Methcathinone
Methenamine
Methionine
Methocarbamol
Methohexital
Methotrexate
Methotrexate
Methoxsalen
Methylcellulose
Methyldopa
Methylergometrine
Methylin
Methylphenidate
Methylphenobarbital
Methylprednisolone
Methyltestosterone
Methysergide
Metiamide
Metoclopramide
Metohexal
Metoprolol
Metrogel
Metronidazole
Metyrapone
Mobic
Moclobemide
Modafinil
Modicon
Monopril
Montelukast
Motrin
Moxidectin
Moxifloxacin
Moxonidine
MS Contin
Mucinex
Mucomyst
Mupirocin
Mupirocin
Muse
Mycitracin
Mycostatin
Myfortic
Mykacet
Mykinac
Myleran
Mylotarg
Mysoline
Phentermine
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

In Europe it is marketed under the names of Movalis, Melox, and Recoxa.

Mechanism of action

Meloxicam is an NSAID and, as such is a cyclooxygenase (COX) inhibitor. It is generally marketed under the name MOBIC. Meloxicam has been shown, especially at its low therapeutic dose, to selectively inhibit COX-2 over COX-1.

Adverse effects

Meloxicam use can result in gastrointestinal toxicity, tinnitus, headache, and rash. The risk of adverse side effects is lower than with piroxicam, diclofenac, or naproxen. Although it does inhibit thromboxane A, it does not appear to do so at levels that would interfere with platelet function.

Approval status

Meloxicam is quite popular in Europe for treatment of rheumatoid arthritis. It has recently (as of 2004) been approved for use in treating osteoarthritis in the United States.


Read more at Wikipedia.org


[List your site here Free!]


Errata
From International Journal of Pharmaceutical Compounding, 9/1/03

1. In "Drug Therapy for Acute and Chronic Pain in the Cat" (IJPC 2002;6(5), an error was made on page 342 in Table 3, Continued. Under the "Feline Dose" column beside the drug Meloxicam, the dosage information should read: 0.2 mg/kg sub-q single dose; 2. 0.2 mg/kg PO on day 2 followed by 0.1 mg/kg PO daily for 4 to 6 days; then decrease the dose to every other day to the smallest effective dose.

2. Also in the same volume and issue, in the "Calculations," an error was made on page 387 in 4.C. The information shown beside the ingredient phenobarbital should be: 2.2 g x 1000 mg/g x 0.4 = 880 mg.

3. In the formula "Fentanyl 100 (mu)g/0.1 mL in a Pluronic Lecithin Organogel (PLO)" (IJPC 2002; 5(1):45), an error was made in the quantity of the fentanyl citrate in the ingredients column. The quantity of this ingredient required to prepare this formula is 157 mg.

4. In the article "Stability of Magnesium Sulfate in 0.9% Sodium Chloride and Lactated Ringers Solutions," (IJPC 1998;2(5)), an error was made on page 385 in the "Experimental Methods" section. The first sentence under the subheading "Preparation and Storage of Test Solutions" lists an incorrect concentration. The actual concentration should be 37 g/L instead of the 37 g/mL shown.

Copyright International Journal of Pharmaceutical Compounding Sep/Oct 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Meloxicam
Home Contact Resources Exchange Links ebay